Compare PTCT & INSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTCT | INSP |
|---|---|---|
| Founded | 1998 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 3.8B |
| IPO Year | 2013 | 2018 |
| Metric | PTCT | INSP |
|---|---|---|
| Price | $77.48 | $138.09 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 15 |
| Target Price | $73.76 | ★ $127.07 |
| AVG Volume (30 Days) | ★ 2.3M | 1.5M |
| Earning Date | 11-04-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.77 |
| EPS | ★ 8.94 | 1.48 |
| Revenue | ★ $1,779,150,000.00 | $882,622,000.00 |
| Revenue This Year | $128.32 | $14.97 |
| Revenue Next Year | N/A | $11.81 |
| P/E Ratio | ★ $8.64 | $92.68 |
| Revenue Growth | ★ 97.54 | 16.81 |
| 52 Week Low | $35.95 | $70.77 |
| 52 Week High | $87.50 | $216.01 |
| Indicator | PTCT | INSP |
|---|---|---|
| Relative Strength Index (RSI) | 54.29 | 76.95 |
| Support Level | $73.03 | $132.39 |
| Resistance Level | $79.03 | $142.56 |
| Average True Range (ATR) | 3.38 | 7.26 |
| MACD | -0.70 | 3.75 |
| Stochastic Oscillator | 29.37 | 90.18 |
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.